Best Cannabis Strain for Pain Relief? What the Evidence Can—and

By Selfie Seeds™ / HWGrow · Built from documented grow experience, owner journals, and supplemental external evidence where useful.

Short answer: there is no scientifically established best cannabis strain for pain relief. No clinical evidence reviewed here identifies a seed-bank cultivar or commercial strain name as the superior choice for pain.

Shop this topic: Browse Cannabis Seeds · CBD · True Selfies

That does not mean all cannabis research is negative. It means the useful evidence is narrower than a strain-name search suggests: human studies have mainly examined cannabinoids and standardized cannabis-based preparations, especially for chronic and neuropathic pain—not named seed lines grown in different environments by different people.[1]

What human research says about pain

The National Center for Complementary and Integrative Health (NCCIH) describes the potential benefit for chronic pain as modest. In one 2018 review summarized by NCCIH, 29% of participants using cannabis or cannabinoids reported at least a 30% reduction in pain, compared with 26% using placebo. NCCIH notes that this small difference may not be meaningful to patients, and adverse events were more common with cannabis/cannabinoids.[1]

For neuropathic pain specifically, NCCIH summarizes low- to moderate-quality evidence of better pain relief than placebo for cannabis-based medicines in a review largely involving nabiximols, a standardized THC/CBD oral spray not approved in the United States. Small study sizes, possible bias, and side-effect-related dropouts limit confidence in that result.[1]

Evidence grade: limited and product-specific. These findings cannot be converted into a recommendation for one flower cultivar, one phenotype, or one packet of cannabis seeds.

Why no strain can honestly be called “best”

A strain name is not a standardized medical formulation. The FDA distinguishes between cannabis cultivars and approved drug products, and it emphasizes that unapproved cannabis products may vary in potency, purity, quality, and labeling accuracy.[2] A seed is even further removed from a tested finished product: it is breeding material that may express different traits across individual plants and growing conditions.

So, when a listing describes aroma, lineage, plant structure, or breeding direction, those are appropriate horticultural details. They are not evidence that a resulting plant will relieve pain—or that it will do so more effectively than another cultivar.

THC, CBD, and terpenes: what they do not establish

THC and CBD are the main cannabinoids commonly discussed by shoppers, and cannabis contains many additional compounds. NCCIH notes that research is continuing on minor cannabinoids and terpenes for possible roles in pain management.[1] That is a research question, not proof that a particular terpene profile or marketing label predicts pain relief in people.

In practical terms, “high CBD,” “indica,” “myrcene-rich,” or a familiar strain name should not be treated as a medical recommendation. The current evidence does not establish a best terpene, cannabinoid ratio, or seed line for pain.

What FDA approval does—and does not—mean

The FDA has not approved the cannabis plant to treat any disease or condition. It has approved specific prescription cannabinoid medicines for limited uses, including certain severe seizure disorders, chemotherapy-related nausea and vomiting, and appetite/weight-loss treatment associated with HIV/AIDS.[2] Those approvals do not establish that ordinary cannabis flower, CBD products, or seeds are proven pain treatments.

A responsible way to shop seed genetics

Choose seeds for transparent, non-medical information: documented parentage, expected plant characteristics, aroma direction, and the breeder’s stated goals. For growers interested in cannabinoid-oriented breeding rather than a medical promise, see our CBD and CBD/THC crosses. Those genetics are categorized by breeding direction and parent information—not marketed as FDA-approved therapies.

If you are comparing seed types, it is also useful to understand what selfing can and cannot preserve in a phenotype. See S1 Cannabis Seeds Explained: What Selfing Does to a Phenotype.

Safety and medical context matter

Do not use cannabis to postpone evaluation of persistent, worsening, unexplained, or severe pain. NCCIH also reports risks including impaired driving, dizziness or fainting risk, cannabis use disorder, and increased psychosis risk in people predisposed to psychotic illness. CBD can interact with other drugs and has its own potential adverse effects.[1]

Speak with a qualified healthcare professional before using cannabis or cannabinoids for pain, particularly if you take prescription medicines, are pregnant or breastfeeding, have a history of psychosis or substance-use problems, or need to drive or operate equipment.

Bottom line

The responsible SEO answer is the evidence-based answer: there is no proven best cannabis strain for pain relief. Some standardized cannabis or cannabinoid preparations have shown small average benefits for certain chronic-pain populations, but that does not validate a particular strain name, seed line, or terpene claim as a treatment. Shop seeds as genetics for cultivation—not as guaranteed medicine.

Sources & References

Source hierarchy prioritizes documented HWGrow/EVYGrows/SelfieSeeds experience. External evidence is supplemental where useful, with counterarguments included when relevant.

[Authoritative Source] Cannabis (Marijuana) and Cannabinoids: What You Need To Know
National Center for Complementary and Integrative Health · National Institutes of Health · 2019
Quoted source: “Some evidence suggests modest benefits of cannabis or cannabinoids for chronic pain.”
Supports / context: Supports the limited, condition-specific evidence for chronic and neuropathic pain; the reported small benefit and more frequent adverse events; ongoing terpene research; and key safety cautions, including drug interactions.
[Authoritative Source] FDA and Cannabis: Research and Drug Approval Process
U.S. Food and Drug Administration · U.S. Food and Drug Administration · 2026
Quoted source: “The FDA has not approved a marketing application for cannabis for the treatment of any disease or condition.”
Supports / context: Supports the distinction between cannabis cultivars and FDA-approved prescription cannabinoid drugs, and the warning that unapproved products can vary in potency, purity, quality, and labeling accuracy.